Abiraterone CAS 154229-19-3 Raw Materials Powder

CAS: 154229-19-3

MF: C24H31NO

Specification​: 99% min Abiraterone Powder

Sample: Abiraterone Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 YearsAbiraterone Powder Usage and Synthesis :
Abiraterone is a targeted cytochrome CYP17(17alpha-hydroxylase /C17, 20-lyase) inhibitor that is hydrolyzed to produce abiraterone, Abiraterone acetate reduces testosterone production by inhibiting cytochrome CYP17 and is indicated for the treatment of metastatic castration-resistant prostate cancer (CRPC) in patients who have received previous chemotherapy containing paclitaxel.
Abiraterone Powder is a medication used to treat prostate cancer. It works by blocking the production of testosterone,  which can fuel the growth of cancer cells. Abiraterone Raw Materials is often used in combination with other  medications, such as prednisone,  to treat advanced prostate cancer that has spread to other parts of the body. Abiraterone CAS 154229-19-3 is taken  orally in the form of a tablet. Common side effects may include fatigue, nausea, diarrhea, and high blood pressure.

Test Method: HPLC

Portal:https:https://henrikang.en.made-in-china.com/

Abiraterone Powder Usage and Synthesis :

Abiraterone is a targeted cytochrome CYP17(17alpha-hydroxylase /C17, 20-lyase) inhibitor that is hydrolyzed to produce abiraterone, Abiraterone acetate reduces testosterone production by inhibiting cytochrome CYP17 and is indicated for the treatment of metastatic castration-resistant prostate cancer (CRPC) in patients who have received previous chemotherapy containing paclitaxel.

Abiraterone Powder is a medication used to treat prostate cancer. It works by blocking the production of testosterone,  which can fuel the growth of cancer cells. Abiraterone Raw Materials is often used in combination with other  medications, such as prednisone,  to treat advanced prostate cancer that has spread to other parts of the body. Abiraterone CAS 154229-19-3 is taken  orally in the form of a tablet. Common side effects may include fatigue, nausea, diarrhea, and high blood pressure.

Application/Function of Abiraterone Powder .

Abiraterone is listed in guidelines as first-line therapy for metastatic CRPC because of its efficacy in patients not receiving docetaxel chemotherapy. Recent studies have shown that abiraterone may benefit patients with locally progressive or metastatic prostate cancer. These results will facilitate the early entry of abiraterone into the first line of treatment for advanced prostate cancer.

Abiraterone is only approved for the treatment of multi-diluted paclitaxel chemotherapy-refractory CPRC, however a better understanding of its mechanism of activity and tolerability adverse effects is critical for the wider clinical use of abiraterone.

In an interim analysis of data from the cOuAA I 302 study, Ryan et al. showed that this study treated abiraterone acetate in combination with prednisone in 1088 patients with metastatic chemotherapy-naïve CPRC, with the primary observations being overall survival and imaging, and the trial confirmed a slowing of cancer spread over a mean time of 8 months relative to the paired group of abiraterone in combination with prednisone. delayed the time to chemotherapy from 16.8 months to 25.

Production method of Abiraterone Powder .

Abiraterone is a prostate cancer treatment drug called Abiraterone, which is not yet available for sale in China and was invented by researchers at the Royal Marsden Hospital in southwest London, a world-renowned cancer research and treatment center.

It can inhibit the production of androgens anywhere in the body with a drug that not only reduces the level of prostate-specific antigen (PSA), which represents tumor activity, but also helps shrink tumors, while showing promise for tumor patients who have had chemotherapy in the past.

It significantly prolongs the lives of patients with advanced prostate cancer, including those whose disease has worsened despite the use of one or two polyene-pyridoxine containing chemotherapeutic agents, with minimal side effects and a good safety profile.

Abiraterone (CB-7598) is a potent CYP17 inhibitor with an IC50 of 2 nM in a cell-free assay. abiraterone (CB-7598) is an inhibitor of androgen biosynthesis.